Karp DD, Hanneken JM,Taylor SH, et al. Three-year survivalin stage IV non-small cell lung cancer( NSCLC) : The importanceof metastatic distribution [ J ]. Open J Thorac Surg, 2013,3:42-46.Three-Year Survival in Stage IV Non-Small Cell Lung Cancer (NSCLC): The Importance of ...
1364P Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE) doi:10.1016/j.annonc.2024.08.1419Annals of OncologyK. jlertP. JainL.E. HendriksF.R. OgliariF. AckerE...
Adrenal metastasectomy is associated with increased survival in non-small cell lung cancer (NSCLC) with isolated adrenal metastases. Although clinical use of adrenal metastasectomy has expanded, indications remain poorly defined. The aim of this study was to evaluate the clinical benefit of adrenal meta...
We analyzed the SEER (surveillance, epidemiology, and end results) program database for cancer specific survival rates in stage IV NSCLC patients who were diagnosed between 1991 and 2004 in the SEER catchment geographic areas. The primary exposure of interest was race. The eight different race ...
Peters S, Chul Cho B, Luft A et al. LBA3 – Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study. Abstract presented at ESMO Immuno-Oncology Congress 2023, December 6-8, 2023.Related Vid...
NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol, 26 (2008), pp. 4617-4625 Google Scholar ...
we saw that the progression-free survival favored nivolumab/ipilimumab in the high TMB group, which was defined as greater than 10 mutations per megabase, versus the chemotherapy, with a hazard ratio of about 0.59. Here, again, we saw that objective response rates were doubled as well. That...
& Hui, R. Response rate and survival at key timepoints with PD-1 blockade versus chemotherapy in PD-L1 subgroups: meta-analysis of metastatic NSCLC trials. JNCI Cancer Spectrum https://doi.org/10.1093/jncics/pkab012 (2021). Addeo, A., Banna, G. L., Metro, G. & Di Maio, M. ...
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan-nxki (Enhertu) compared with ado-trastuzumab emtansine (Kadcyla; T-DM1), according to updated results from the phase 3 DESTINY...
Peters reported. Notably, the six-year overallsurvival rateswere substantially higher, reaching 22% vs. 13% and 16% vs. 5%, respectively, for patients with tumor PD-L1 ≥1% or <1%. These outcomes signify an advance in the treatment